Unicycive Therapeutics (UNCY) Retained Earnings (2020 - 2026)
Unicycive Therapeutics posted quarterly Retained Earnings of -$140.6 million for Q1 2026, down 10.02% year-on-year from -$156.2 million in Q1 2025, and down 14059900.0% on a QoQ basis from -$1000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Retained Earnings data on file, last reported at -$140.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 10.02% year-over-year to -$140.6 million; the trailing twelve-month figure through Mar 2026 stood at -$140.6 million (down 10.02% YoY), and the FY2025 full-year result was -$1000.0, up 100.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$140.6 million, down from -$1000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at -$1000.0 in Q4 2025 and bottomed at -$140.6 million in Q1 2026.
- The 5-year median for Retained Earnings is -$64.5 million (2023), against an average of -$68.1 million.
- The widest annual swing landed in 2022, when Retained Earnings sank 189.41%; it then soared 100.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$34.0 million in 2022, then plunged by 89.72% to -$64.5 million in 2023, then tumbled by 57.01% to -$101.3 million in 2024, then jumped by 100.0% to -$1000.0 in 2025, then sank by 14059900.0% to -$140.6 million in 2026.
- The last three Retained Earnings figures came in at -$140.6 million (Q1 2026), -$1000.0 (Q4 2025), and -$113.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -140.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.60 Mn |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -113.16 Mn |
| Jun 30, 2025 | -107.10 Mn |
| Mar 31, 2025 | -127.80 Mn |
| Dec 31, 2024 | -101.27 Mn |
| Sep 30, 2024 | -79.75 Mn |
| Jun 30, 2024 | -75.65 Mn |
| Mar 31, 2024 | -85.50 Mn |
| Dec 31, 2023 | -64.50 Mn |
| Sep 30, 2023 | -56.70 Mn |
| Jun 30, 2023 | -52.41 Mn |
| Mar 31, 2023 | -48.57 Mn |
| Dec 31, 2022 | -34.00 Mn |
| Sep 30, 2022 | -28.67 Mn |
| Jun 30, 2022 | -23.11 Mn |
| Mar 31, 2022 | -19.48 Mn |
| Dec 31, 2021 | -15.94 Mn |
| Sep 30, 2021 | -13.19 Mn |
| Jun 30, 2021 | -7.99 Mn |
| Dec 31, 2020 | -5.92 Mn |